Analysts forecast the Global Osteoporosis Drugs market to grow at a CAGR of 3.98 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Osteoporosis Drugs market has also been witnessing the increasing awareness of bone health education. However, the multiple patent expiries could pose a challenge to the growth of this market. Global Osteoporosis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Osteoporosis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors dominating this space are Amgen Inc., Eli Lilly & Co., Merck & Co. Inc., and Novartis AG. Other vendors mentioned in the report are Abiogen Pharma SpA, F. Hoffmann La Roche Ltd., GlaxoSmithKline plc, Ligand Pharmaceuticals Inc., NPS Pharma Inc., and Pfizer Inc.
Inquire Before buying the Report @ http://www.sandlerresearch.org/inquire-before-buying?rname=13836
Key questions answered in this report:
What will the market size be in 2016/2018 and what will the growth rate be? What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
Table Of Contents
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Osteoporosis Drugs Market in the US
06.3.1 Market Size and Forecast
Please join StudyMode to read the full document